Metabolic disorders and gut microbiota*

Authors

  • Anna Kotrova St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation https://orcid.org/0000-0002-9430-6339
  • Alexandr Shishkin St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
  • Maria Lukashenko St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation

DOI:

https://doi.org/10.21638/spbu11.2020.302

Abstract

Obesity, type 2 diabetes mellitus, metabolic syndrome are metabolic widespread disorders that arise both under the influence of external factors (physical inactivity, high-calorie diet) and under the influence of internal factors. The latter includes the intestinal microbiota which deserves more and more attention in developing new strategies for the correction of metabolic diseases. The discovery of new approaches for the gut microbiota study (metagenomic, metabolomic) gives a new insight into the diversity and involvement of intestinal bacteria in the metabolic processes of the whole organism. This article are reviewed the mechanisms of the gut bacteria impact on lipid and carbohydrate metabolism, the relationship of bacteria species and their metabolites with tissue insulin sensitivity, body mass index. Special attention in the regulation of tissue insulin sensitivity is paid to the role of short-chain fatty acids and secondary bile acids, which are metabolites of gut bacteria. Understanding the influence of human microbiota and its metabolites on lipid and carbohydrate metabolism provides the basis for the development of new approaches to the prevention and treatment of socially significant metabolic diseases such as type 2 diabetes mellitus, obesity, metabolic syndrome.

Keywords:

microbiota, metabolic disorders, lipopolysaccharide, short-chain fatty acids, bile acids

Downloads

Download data is not yet available.
 

References


References

Guevara-Cruz M., Flores-López A. G., Aguilar-López M., Sánchez-Tapia M., Medina-Vera I., Díaz D., Tovar A. R., Torres N. Improvement of Lipoprotein Profile and Metabolic Endotoxemia by a Lifestyle Intervention That Modifies the Gut Microbiota in Subjects with Metabolic Syndrome. J. Am. Heart Assoc., 2019, vol. 8, no. 17, article ID 012401.

Pokrovskaya E. V., Shamkhalova M. Sh., Shestakova M. V. New views on the state of the intestinal microbiota in obesity and type 2 diabetes. Sakharnyi diabet,2019, vol. 22, no. 3, pp. 253–262. (In Russian)

Iacobini C., Pugliese G., Blasetti Fantauzzi C., Federici M., Menini S. Metabolically healthy versus metabolically unhealthy obesity. Metabolism, 2019, vol. 92, pp. 51–60.

Borshchev Y. Y., Ermolenko E. I. Metabolic syndrome and intestinal microecology. Transliatsionnaia meditsina, 2014, no. 1, pp. 19–28. (In Russian)

Kravchuk E. N., Neymark A. E., Grineva E. N., Galagudza M. M. The role of gut microbiota in metabolic regulation. Sakharnyi diabet, 2016, vol. 19, no. 4, pp. 280–285. (In Russian)

Plotnikova E. Y., Krasnov O. A. Metabolic syndrome and intestinal micro flora: what overall? Eksperimentalnaia i klinicheskaia gastroenterologia, 2015, vol. 112, no. 12, pp. 64–73. (In Russian

Eckburg P. B., Bik E. M., Bernstein C. N., Purdom E., Dethlefsen L., Sargent M., Gill S. R., Nelson K. E., Relman D. A. Diversity of the human intestinal microbial flora.Science, 2005, vol. 308, no. 5728, pp. 1635–1638.

O’Hara A. M, Shanahan F. The gut flora as a forgotten organ. EMBO Reports, 2006, vol. 7, no. 7,pp. 688–693.

Rajilić-Stojanović M., de Vos W. M. The first 1000 cultured species of the human gastrointestinal microbiota.FEMS Microbiol. Rev., 2014, vol. 38, no. 5, pp. 996–1047

Tap J., Mondot S., Levenez F., Pelletier E., Caron C., Furet J. P., Ugarte E., Muñoz-Tamayo R., Paslier D. L., Nalin R., Dore J., Leclerc M. Towards the human intestinal microbiota phylogenetic core.Environ. Microbiol., 2009, vol. 11, no. 10, pp. 2574–2584.

Jandhyala S. M., Talukdar R., Subramanyam C., Vuyyuru H., Sasikala M., Nageshwar Reddy D. Role of the normal gut microbiota. World J. Gastroenterol., 2015, vol. 21, no. 29, pp. 8787–8803.

Sekirov I., Russell S. L., Antunes L. C., Finlay B. B. Gut microbiota in health and disease. Physiol. Rev.,2010, vol. 90, no. 3, pp. 859–904.

Belzer C., de Vos W. M. Microbes inside — from diversity to function: the case of Akkermansia. ISME J.,2012, vol. 6, no. 8, pp. 1449–1458.

Tremaroli V., Backhed F. Functional interactions between the gut microbiota and host metabolism.Nature, 2012, vol. 489, no. 7415, pp. 242–249.

Erejuwa O. O., Sulaiman S. A., Ab Wahab M. S. Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int. J. Mol. Sci., 2014, vol. 15, no. 3, pp. 4158–4188.

Zhernakova A., Kurilshikov A., Bonder M. J., Tigchelaar E. F., Schirmer M., Vatanen T., Mujagic Z., Vich Vila A., Falony G., Vieira-Silva S., Jun Wang, Imhann F., Brandsma E., Jankipersadsing S. A., Joossens

M., Cenit M. C., Deelen P., Swertz M. A., Weersma R. K., Feskens E. J. M., Netea M. G., Gevers D.,

Jonkers D., Franke L., Aulchenko Yu. S., Huttenhower C., Raes J., Hofker M. H., Xavier R. J., Wijmenga

C., Jingyuan Fu. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science, 2016, vol. 352, no. 6285, pp. 565–569.

Chassaing B., Koren O., Goodrich J. K., Poole A. C., Srinivasan S., Ley R. E., Gewirtz A. T. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature, 2015,vol. 519, no. 7541, pp. 92–96.

Neal M. D., Leaphart C., Levy R., Prince J., Billiar T. R, Watkins S., Jun Li, Cetin S., Ford H., Schreiber A., Hackam D. J. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J. Immunol., 2006, no. 176, pp. 3070–3079.

Aitbaev K. A., Murkamilov I. T. Obesity and metabolic syndrome: pathophysiological role of gut microbiota and potential of the alternative therapy. Complex Issues of Cardiovascular Diseases, 2017,no. 3, pp. 120–130.

Wang J., Li W., Wang C., Wang L., He T., Hu H., Song J., Cui C., Qiao J., Qing L., Li L., Zang N.,Wang K., Wu C., Qi L., Ma A., Zheng H., Hou X., Liu F., Chen L. Enterotype Bacteroides is Associated with a High Risk in Patients with Diabetes: A Pilot Study. J. Diabetes Res., 2020, vol. 2020, article ID6047145.

Kurmangulov A. A, Dorodneva E. F, Isakova D. N. Functional activity of intestinal microbiota with metabolic syndrome. Ozhirenie i metabolizm, 2016, vol. 13, no. 1, pp. 16–19. (In Russian)

Faith J. J., Guruge J. L., Charbonneau M., Subramanian S., Seedorf H., Goodman A. L., Clemente J. C., Knight R., Heath A. C., Leibel R. L., Rosenbaum M., Gordon J. I. The long-term stability of the human gut microbiota. Science, 2013, vol. 341, no. 6141, pp. 1237439.

Chambers E. S, Viardot A., Psichas A., Morrison D. J., Murphy K. G., Zac-Varghese S. E. K., Mac-Dougall K., Preston T., Tedford C., Finlayson G. S., Blundell J. E., Bell J. D., Thomas E. L., Mt-Isa S., Ashby D., Gibson G. R., Kolida S., Dhillo W. S., Bloom S. R., Morley W., Clegg S., Frost G. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut., 2015, vol. 64, no. 11, pp. 1744–1754.

Perry R. J., Peng L., Barry N. A, Cline G. W., Zhang D., Cardone R. L., Petersen K. F., Kibbey R. G., Goodman A. L., Shulman G. I. Acetate mediate a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature, 2016, vol. 534, no. 7606, pp. 213–217.

Bäckhed F., Ding H., Wang T., Hooper L. V., Koh G. Y., Nagy A., Semenkovich C. F., Gordon J. I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA, 2004, vol. 101, no. 44, pp. 15718–15723.

Chaplin A. V., Rebrikov D. V., Boldyreva M. N. The human microbiome. Bulletin of Pirogov Medical University, 2017, no. 2, pp. 5–13.

Volovnikova V. A., Kotrova A. D., Ivanova K. A., Ermolenko E. I., Shishkin A. N. The role of gut microbiota in the development of obesity. Juvenis Scientia, 2019, no. 6, pp. 4–10. (In Russian)

Santos-Marcos J. A., Perez-Jimenez F., Camargo A. The role of diet and intestinal microbiota in the development of metabolic syndrome. Journal of Nutritional Biochemistry, 2019, no. 70, pp. 1–27.

Liu R., Hong J., Xu X., Feng Q., Zhang D., Gu Ya., Shi J., Zhao S., Liu W., Wang X., Xia H., Liu Z., Cui B., Liang P., Xi L., Jin J., Ying X., Wang X., Zhao X., Li W., Jia H., Lan Z., Li F., Wang R., Sun Y., Yang M., Shen Y., Jie Z., Li J., Chen X., Zhong H., Xie H., Zhang Y., Gu W., Deng X., Shen B., Xu X., Yang H.,Xu G., Bi Y., Lai S., Wang J., Qi L., Madsen L., Wang J., Ning G., Kristiansen K., Wang W. Affiliations expand Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention.Nat. Med., 2017, vol. 23, no. 7, pp. 859–868.

Ganesan K., Chung S. K., Vanamala J., Xu B. Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes. Int. J. Mol. Sci., 2018, vol. 19, no. 12, article ID 3720.

Gontsaryuk D., Khristich T. The role of microbiota in the course and development of metabolic processes in chronic pancreatitis. Bulletin of the Club of Pancreatologists, 2017, vol. 38, no. 4, pp. 22–26.

Kotrova A. D., Shishkin A. N., Semenova O. I., Slepykh L. A. The role of intestinal microbiota in the development of metabolic syndrome. Eksperimentalnaia i klinicheskaia gastroenterologia,2019, vol. 172,no. 12, pp. 101–108.

Turdiev S. M. Metabolic syndrome — an urgent problem of the XXI century. Sbornik nauchnykh trudov po materialam Mezhdunarodnoi nauchnoi konferentsii, posviashchennoi 85-letiiu Kurskogo gosudarstvennogo meditsinskogo universiteta.Kursk, Kurskii gosudarstvennyi meditsinskii universitet Publ., 2020, pp. 304–308.

Downloads

Published

2020-12-28

How to Cite

Kotrova, A., Shishkin, A. ., & Lukashenko, M. (2020). Metabolic disorders and gut microbiota* . Vestnik of Saint Petersburg University. Medicine, 15(3), 177–183. https://doi.org/10.21638/spbu11.2020.302

Issue

Vol. 15 No. 3 (2020)

Section

Internal medicine

License

Articles of "Vestnik of Saint Petersburg University. Medicine" are open access distributed under the terms of the License Agreement with Saint Petersburg State University, which permits to the authors unrestricted distribution and self-archiving free of charge.

Most read articles by the same author(s)